Would you still offer durvalumab after chemoradiation in patients with stage III NSCLC whose treatment was delayed due to prolonged recovery from chemoradiation?

The PACIFIC study, which evaluated the use of durvalamab after completion of chemotherapy and radiation (both sequential and concurrent) is a landmark trial demonstrating improved survival for those receiving immunotherapy. The design of the study required that durvalamab commence within 42 days of ...

In general, I would follow the entry/eligibility criteria as described in the PACIFIC trial - i.e. up to 42 days/six weeks after completion of chemoradiation (last dose of radiation). In fact, in the supplementary data from the 2018 NEJM report, there was a trend towards improvement in OS with treat...